(Q36666652)

15 August 2017

1 reference

title

Non-small cell lung cancer. Part II: Treatment (English)

1 reference

15 August 2017

Non-small cell lung cancer Part II: Treatment (English)

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

5 November 2022

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

5 November 2022

author name string

D. C. Ihde

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1713139

5 November 2022

J. D. Minna

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1713139

5 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1713139

5 November 2022

publication date

1 May 1991

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:014702729190012Y?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

https://api.elsevier.com/content/article/PII:014702729190012Y?httpAccept=text/plain

5 November 2022

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Current Problems in Cancer

5 November 2022

published in

1 reference

15 August 2017

15

1 reference

15 August 2017

105-154

1 reference

15 August 2017

3

1 reference

Therapy of stage I and stage II non-small cell lung cancer

15 August 2017

2

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Preoperative assessment as a predictor of mortality and morbidity after lung resection

5 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Results of sleeve lobectomy for bronchogenic carcinoma in 101 patients

5 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group

5 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases

5 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Blood transfusion and lung cancer recurrence

5 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Factors affecting survival in superior sulcus tumors

5 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Tracheal sleeve pneumonectomy for bronchogenic carcinoma: report of 55 cases

5 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Implications of histologically reported residual tumour on the bronchial margin after resection for bronchial carcinoma

5 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Carcinoma of the bronchus with unsuspected microscopic resection-line involvement

5 November 2022

23

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Significance of extramucosal residual tumor at the bronchial resection margin

5 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience.

5 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized trial of surgery in the treatment of single metastases to the brain.

5 November 2022

27

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies

5 November 2022

28

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Radiotherapy of squamous, adeno- and large cell carcinoma of the lung

5 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

5 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Predictors of radiation response in lung cancer. A clinico-pathobiological analysis

5 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Is immediate chest radiotherapy obligatory for any or all patients with limited-stage non-small cell carcinoma of the lung? Yes

5 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Is immediate radiation therapy indicated for patients with unresectable non-small cell lung cancer? No

5 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Radical irradiation with the split-course technique in carcinoma of the lung

5 November 2022

36

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Reassessment of radiation therapy for the management of lung cancer in patients with chronic pulmonary disease.

5 November 2022

37

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Radiation therapy for medically inoperable stage I and II non-small cell lung cancer

5 November 2022

38

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Analysis of the influence of elective nodal irradiation on postirradiation pulmonary function

5 November 2022

39

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Improved survival of patients with unresectable non-small-cell bronchogenic carcinoma by an innovated high-doseEn-Bloc radiotherapeutic approach

5 November 2022

40

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the radiation therapy oncology group

5 November 2022

41

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Comparison of split-course radiation therapy and continuous radiation therapy for unresectable bronchogenic carcinoma: 5 year results

5 November 2022

42

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized study of split-course radiotherapy of lung cancer: Long term results

5 November 2022

43

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group

5 November 2022

44

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial

5 November 2022

45

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Radiotherapy of regional epidermoid carcinoma of the lung: a study in fractionation

5 November 2022

46

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung.

5 November 2022

47

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

5 November 2022

48

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Once-a-week vs conventional daily radiation treatment for lung cancer: final report.

5 November 2022

49

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Total (half-body) systemic irradiation for occult metastases in non-small cell lung cancer: an Eastern Cooperative Oncology Group pilot report

5 November 2022

50

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Combined surgery, intraoperative brachytherapy, and postoperative external radiation in stage III non-small cell lung cancer

5 November 2022

51

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Neutron radiation therapy for unresectable non-small-cell carcinoma of the lung. A review.

5 November 2022

52

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial

5 November 2022

53

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Thoracic irradiation with or without levamisole (NSC #177023) in unresectable non-small cell carcinoma of the lung: a phase III randomized trial of the RTOG

5 November 2022

54

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

The characteristics of long-term survivors of lung cancer treated with radiation

5 November 2022

55

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer

5 November 2022

56

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Indications for and resuls of irradiation of carcinoma of the lung.

5 November 2022

57

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small-cell lung cancer treated with radiation therapy

5 November 2022

58

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Radiotherapy alone for patients with operable carcinoma of the lung

5 November 2022

60

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer

5 November 2022

61

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

External radiation in the management of superior sulcus tumor

5 November 2022

62

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Superior sulcus tumors: Results of irradiation of 36 patients

5 November 2022

63

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Comparison of treatment policies in inoperable bronchial carcinoma

5 November 2022

64

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo.

5 November 2022

65

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy?

5 November 2022

66

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Basis for new strategies in postoperative radiotherapy of bronchogenic carcinoma

5 November 2022

67

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Postresection Irradiation for Primary Lung Cancer

5 November 2022

68

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Carcinoma of the Lung: Results of Treatment over Ten Years

5 November 2022

69

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design

5 November 2022

70

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung

5 November 2022

71

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Preoperative irradiation of cancer of the lung: Final report of a therapeutic trial.A collaborative study

5 November 2022

72

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

An aggressive approach to marginally resectable lung cancer

5 November 2022

74

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

High-dose cisplatin and vinblastine infusion with or without radiation therapy in patients with advanced non-small-cell lung cancer

5 November 2022

76

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Prophylactic cranial irradiation in adenocarcinoma of the lung. A possible role

5 November 2022

77

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer

5 November 2022

79

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Radiation Therapy in Bronchogenic Carcinoma

5 November 2022

80

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Improvement in regional ventilation and perfusion after radiotherapy for unresectable carcinoma of the bronchus

5 November 2022

81

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Effect of radiation therapy on bronchial obstruction due to bronchogenic carcinoma

5 November 2022

82

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

High dose rate intraluminal irradiation in recurrent endobronchial carcinoma

5 November 2022

83

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Prospective evaluation of a watch policy in patients with inoperable non-small cell lung cancer

5 November 2022

85

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Role of systemic therapy in advanced non-small-cell lung cancer

5 November 2022

86

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review

5 November 2022

89

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Combination chemotherapy for advanced adenocarcinoma of the lung. A review

5 November 2022

90

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Evaluation of response criteria in advanced lung cancer

5 November 2022

92

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Measurability of non-small-cell lung cancer on chest radiographs.

5 November 2022

93

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Alkylating agents in bronchogenic carcinoma

5 November 2022

94

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer

5 November 2022

95

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer

5 November 2022

97

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs

5 November 2022

98

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung

5 November 2022

99

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Metastatic non-small cell bronchogenic carcinoma: a randomized trial of sequential vs combination chemotherapy

5 November 2022

102

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial

5 November 2022

103

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force

5 November 2022

104

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

5 November 2022

105

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study

5 November 2022

107

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Combination versus sequential single-agent chemotherapy in the treatment of patients with advanced non-small cell lung cancer

5 November 2022

108

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer

5 November 2022

109

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens

5 November 2022

110

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment

5 November 2022

111

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm

5 November 2022

112

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

5 November 2022

114

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium

5 November 2022

115

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules

5 November 2022

117

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen

5 November 2022

118

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma

5 November 2022

119

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung

5 November 2022

120

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer

5 November 2022

121

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer.

5 November 2022

122

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study

5 November 2022

123

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

5 November 2022

124

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study

5 November 2022

125

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

5 November 2022

126

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Treatment of advanced non-small cell lung cancer: the Southwest Oncology Group experience

5 November 2022

127

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center

5 November 2022

128

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer

5 November 2022

129

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

5 November 2022

131

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer

5 November 2022

132

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment

5 November 2022

133

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

5 November 2022

134

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Clinical research on the treatment of locally advanced lung cancer.Final report of VALG protocol 13 limited

5 November 2022

136

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Inoperable non-small cell lung cancer: radiation with or without chemotherapy

5 November 2022

137

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

5 November 2022

138

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for nonsmall-cell lung cancer. A randomized study

5 November 2022

140

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized study evaluating radiotherapy versus chemotherapy in patients with inoperable non-small cell lung cancer

5 November 2022

141

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Protochemotherapy in non-small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report

5 November 2022

142

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer

5 November 2022

143

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer

5 November 2022

144

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0).

5 November 2022

145

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients

5 November 2022

146

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Combined modality therapy for locally advanced non-small cell lung carcinoma.

5 November 2022

147

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Neoadjuvant therapy of stage III non-small cell lung cancer

5 November 2022

149

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Adjuvant cancer chemotherapy after resection of carcinoma of the lung

5 November 2022

150

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung

5 November 2022

151

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma

5 November 2022

152

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Combination chemotherapy with and without the methanol-extracted residue of bacillus Calmette-Guerin (MER) in extensive non-small-cell lung cancer: a prospective randomized study for the Piedmont Oncology Association

5 November 2022

156

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma: a Veterans Administration Lung Cancer Group Study

5 November 2022

157

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung

5 November 2022

159

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation

5 November 2022

160

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer

5 November 2022

161

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer

5 November 2022

162

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75

5 November 2022

163

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188.

5 November 2022

164

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Treatment of malignant pleural and pericardial effusions

5 November 2022

169

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Pleuroperitoneal shunting for malignant pleural effusions.

5 November 2022

170

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

A two-year experience with the neodymium-YAG laser in endobronchial obstruction

5 November 2022

172

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Nd:YAG laser bronchoscopy. A five-year experience with 1,396 applications in 1,000 patients

5 November 2022

173

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Photodynamic therapy of endobronchial malignancies

5 November 2022

174

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

Predicting the response of obstructive endobronchial tumors to photodynamic therapy

5 November 2022

175

1 reference

https://api.crossref.org/works/10.1016/0147-0272(91)90012-Y

5 November 2022

Identifiers

1 reference

15 August 2017

1 reference